These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1439111)

  • 1. [Factors influencing the effect of ursodeoxycholic acid therapy in chronic hypertransaminasemia].
    Buongiorno G; Quaranta GM; Guerra V; Misciagna G; Manghisi OG
    Recenti Prog Med; 1992 May; 83(5):298-302. PubMed ID: 1439111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of ursodeoxycholic acid in patients with liver cirrhosis and chronic hypertransaminasemia].
    Buongiorno G; Quaranta GM; Penna A; Guerra V; Misciagna G; Manghisi OG
    Minerva Gastroenterol Dietol; 1994 Mar; 40(1):31-6. PubMed ID: 8204703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
    Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of therapy with bis-hemisuccinate of ursodeoxycholic acid bisodium salt in patients with chronic hepatitis].
    Pinto A; Parini P; Novelli V; Zagari M; Sangermano A; Orsini M; Salzetta A; Buffarini F; Roda E
    Minerva Med; 1992 Jun; 83(6):359-61. PubMed ID: 1352868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis.
    Simko V; Michael S; Prego V
    Am J Gastroenterol; 1994 Mar; 89(3):392-8. PubMed ID: 8122652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.
    Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L
    Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with chronic hepatitis using ursodeoxycholic acid.
    Nambu M; Iijima T
    Trop Gastroenterol; 1993; 14(2):59-65. PubMed ID: 8291125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
    Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
    Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simple blood tests can predict compensated liver cirrhosis in patients with chronic hepatitis C.
    Luo JC; Hwang SJ; Chang FY; Chu CW; Lai CR; Wang YJ; Lee PC; Tsay SH; Lee SD
    Hepatogastroenterology; 2002; 49(44):478-81. PubMed ID: 11995477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of hypertransaminasemia in adult celiac patients and effect of gluten-free diet.
    Bardella MT; Fraquelli M; Quatrini M; Molteni N; Bianchi P; Conte D
    Hepatology; 1995 Sep; 22(3):833-6. PubMed ID: 7657290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
    Laurin J; Lindor KD; Crippin JS; Gossard A; Gores GJ; Ludwig J; Rakela J; McGill DB
    Hepatology; 1996 Jun; 23(6):1464-7. PubMed ID: 8675165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ursodeoxycholic hemisuccinate in the treatment of chronic active hepatitis. A controlled clinico-therapeutic study].
    Buzzelli G; Moscarella S; Focardi G; Dattolo P; Giusti A; Calviani L; Relli P; Gentilini P
    Minerva Med; 1992 Sep; 83(9):537-40. PubMed ID: 1436604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
    Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
    Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic active hepatitis and primary biliary cirrhosis with ursodeoxycholic acid.
    Güldütuna S; Leuschner U; Imhof M; Zimmer G
    Z Gastroenterol; 1992 Mar; 30 Suppl 1():49-54. PubMed ID: 1449017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.
    Rino Y; Tarao K; Morinaga S; Ohkawa S; Miyakawa K; Hirokawa S; Masaki T; Tarao N; Yukawa N; Saeki H; Takanashi Y; Imada T
    Anticancer Res; 2006; 26(3B):2221-6. PubMed ID: 16821591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease.
    Puoti C; Magrini A; Filippi T; Annovazzi G; Pannullo A
    Eur J Gastroenterol Hepatol; 1995 Feb; 7(2):151-4. PubMed ID: 7712308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ursodeoxycholic acid for the treatment of chronic diseases of the liver. Short-term results].
    Pisciotta G; Scialabba A; Montalto G; Di Marco C; Fontana N; Ruggeri I; Sausa F; Bracco S; Notarbartoló A
    Minerva Gastroenterol Dietol; 1991; 37(1):29-33. PubMed ID: 1873327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection.
    Sheth SG; Flamm SL; Gordon FD; Chopra S
    Am J Gastroenterol; 1998 Jan; 93(1):44-8. PubMed ID: 9448172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.